Description

• General description: Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Cilostazol is a dihydro-quinolinone derivative, that is predominantly used as an anti-platelet and vasodilatory agent. It acts by inhibition of cyclic adenosine monophosphate (cAMP) phosphodiesterase, which results in elevation of cAMP levels in platelets and blood vessels, thus inhibiting platelets aggregation.[1]
• Application: Cilostazol may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by chromatography.[2][3]
• Analysis Note: These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
• Other Notes: This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
• Footnote: To see an example of a Certificate of Analysis for this material enter LRAA3090 in the slot below. This is an example certificate only and may not be the lot that you receive.
• Recommended products: Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.